Genetically Modified NK-92 Cells With CD16 Safety Switch
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
NK-92 cells, despite their high cytolytic activity, lack the Fc receptor CD16, preventing them from effectively engaging in antibody-dependent cellular cytotoxicity (ADCC) with monoclonal antibodies, leading to potential tumor relapse in cancer treatment.
Innovation Solution
Genetically modify NK-92 cells to express the Fc receptor CD16, optionally with interleukin-2 targeting to the endoplasmic reticulum and a suicide gene like inducible caspase 9, and administer them concurrently or sequentially with monoclonal antibodies to enhance cancer treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If NK-92 cells are used for cancer treatment, then cytolytic activity is improved, but ability to engage in ADCC with monoclonal antibodies deteriorates due to lack of Fc receptor CD16
Solution Approach 1:
The patent applies parameter changes by genetically modifying NK-92 cells to alter their surface receptor expression profile. Specifically, the cells are engineered to downregulate or eliminate endogenous Fc receptors while upregulating chimeric Fc receptors (such as CD16 variants) with modified binding parameters. This enables the cells to maintain cytolytic activity while gaining enhanced ability to engage in ADCC with monoclonal antibodies, effectively resolving the contradiction between cytolytic strength and ADCC adaptability.
2Productivity
If genetically modified NK-92 cells are administered with monoclonal antibodies, then cancer treatment efficacy is improved, but risk of adverse effects and uncontrolled proliferation worsens
Solution Approach 1:
The patent implements beforehand cushioning by incorporating suicide genes (such as HSV-thymidine kinase or inducible caspase 9) into the genetically modified NK-92 cells before administration. These safety switches are designed to be activated only when needed, providing a pre-prepared mechanism to eliminate the cells if they exhibit uncontrolled proliferation or cause adverse effects. This approach cushions against potential harms while allowing the cells to exert their therapeutic effect during normal operation.
Solution Approach 2:
The patent uses inducible caspase 9 as an intermediary safety mechanism. This suicide gene system acts as a mediator between the therapeutic NK-92 cells and the patient's safety, allowing controlled elimination of the cells through administration of a small molecule inducer (AP1903). The intermediary enables precise control over cell persistence, allowing the cells to provide sustained anti-tumor activity while offering a safety valve to terminate their function if adverse effects occur.
3Adaptability or versatility
If Fc receptor CD16 is expressed on NK-92 cells, then ADCC capability is improved, but loss of cytolytic activity may occur
Solution Approach 1:
The patent applies local quality by creating spatial and functional differentiation in the NK-92 cell population. Different subsets or clones of cells are engineered with different functional characteristics: some cells are optimized for ADCC with high Fc receptor expression, while others maintain high cytolytic activity with lower Fc receptor expression. This local quality differentiation allows the overall cell population to exhibit both ADCC capability and cytolytic activity without one function compromising the other, as each cell subset specializes in one primary mechanism.
Data Source
AI summary
This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.